Cargo Therapeutics, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
A director of CARGO Therapeutics, Kapil Dhingra, disposed of 25,000 stock options following the company's merger with Concentra Biosciences.
CARGO Therapeutics Director Krishnan Viswanadhan disposed of all beneficial ownership in the company following its acquisition by Concentra Biosciences.
CARGO Therapeutics Director David Lubner's stock options were canceled and converted into cash and contingent value rights following the company's acquisition by Concentra Biosciences.
A director of CARGO Therapeutics, Inc. disposed of stock options following the company's acquisition by Concentra Biosciences, LLC.
CARGO Therapeutics Director Jane Henderson disposed of 25,000 stock options following the company's acquisition by Concentra Biosciences for $4.379 cash and one CVR per share.
A director of CARGO Therapeutics, Abraham Bassan, disposed of stock options following the company's acquisition by Concentra Biosciences.
CARGO Therapeutics Director Reid Huber disposed of 25,000 stock options following the company's acquisition by Concentra Biosciences for $4.379 cash plus CVRs per share.
Anup Radhakrishnan, Interim CEO of CARGO Therapeutics, disposed of all common stock and stock options following the company's acquisition by Concentra Biosciences.
Anup Radhakrishnan, Interim CEO, CFO, and COO of CARGO Therapeutics, Inc., sold 1,632 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.
CARGO Therapeutics, Inc. Director Krishnan Viswanadhan was granted 25,000 stock options with an exercise price of $4.35, vesting over one year or by the next Annual Meeting.
CARGO Therapeutics, Inc. Director Reid M. Huber was granted 25,000 stock options with an exercise price of $4.35, aligning his interests with shareholders.
CARGO Therapeutics, Inc. Director Abraham Bassan was granted 25,000 stock options with an exercise price of $4.35, vesting over one year or until the next annual meeting.
CARGO Therapeutics, Inc. Director Kapil Dhingra was granted 25,000 stock options with an exercise price of $4.35, vesting over one year or by the next annual meeting.
CARGO Therapeutics, Inc. Director David Charles Lubner was granted 25,000 stock options with an exercise price of $4.35, vesting over one year or by the next annual meeting.
CARGO Therapeutics, Inc. Director Jane Henderson was granted 25,000 stock options with an exercise price of $4.35, vesting over one year or by the next annual meeting.
John A. Orwin, a Director at CARGO Therapeutics, Inc. (CRGX), was granted 25,000 stock options with an exercise price of $4.35, vesting over one year or by the next annual meeting.
Anup Radhakrishnan, Interim CEO, CFO, and COO of Cargo Therapeutics, sold shares to cover tax withholding obligations related to vesting restricted stock units.
Anup Radhakrishnan, Interim CEO, CFO, and COO of Cargo Therapeutics, acquired 72,500 restricted stock units (RSUs) on May 12, 2025, under a retention program.
Anup Radhakrishnan, Interim CEO, CFO, and COO of Cargo Therapeutics, sold 1,629 shares of common stock to cover tax withholding obligations related to vesting restricted stock units.
Anup Radhakrishnan, CFO and COO of Cargo Therapeutics, reports acquiring and disposing of common stock and restricted stock units.
Ginna Laport, Chief Medical Officer of CARGO Therapeutics, reports acquiring 50,000 shares of common stock through restricted stock units (RSUs).
Gina Chapman, President & CEO of Cargo Therapeutics, reports acquiring 200,000 shares of common stock and disposing of 303,905 shares.
Shishir Gadam, Chief Technical Officer of Cargo Therapeutics, acquired 60,000 shares of common stock on March 14, 2025, through restricted stock units.
Anup Radhakrishnan, CFO of Cargo Therapeutics, acquired 40,000 stock options with a $16 exercise price, vesting monthly over four years.
Gina Chapman, President and CEO of Cargo Therapeutics, exercised stock options and sold shares of common stock on September 18 and 19, 2024, according to a Form 4 filing with the SEC.
Anup Radhakrishnan, CFO of Cargo Therapeutics, exercised stock options and sold shares on September 18, 2024, according to a Form 4 filing with the SEC.
Kapil Dhingra, a director at Cargo Therapeutics, acquired stock options for 11,871 shares on June 4, 2024.
Abraham Bassan, a director of Cargo Therapeutics, acquired stock options for 23,742 shares on June 4, 2024.
Krishnan Viswanadhan, a director at Cargo Therapeutics, acquired stock options for 23,742 shares on June 4, 2024.
David Lubner, a director of Cargo Therapeutics, acquired stock options for 23,742 shares on June 4, 2024, at an exercise price of $19.17.